Platelet function and coagulation in patients with hepatobiliary disorders receiving cefotetan prophylaxis

Area of Science:

• Pharmacology
• Hepatology
• Clinical Medicine

Background:

• Cephalosporins can be associated with bleeding disturbances.
• Patients with hepatobiliary disorders may be at increased risk for coagulation abnormalities.
• The safety profile of cefotetan regarding hemostasis in this patient population requires investigation.

Purpose of the Study:

• To evaluate the effect of cefotetan on platelet function and coagulation factors in patients with hepatobiliary disorders.
• To determine if cefotetan administration is associated with an increased risk of bleeding complications in this specific patient group.

Main Methods:

• Eighteen patients with hepatobiliary disorders undergoing invasive biliary tract investigations were enrolled.
• Patients received cefotetan intravenously at 1 g twice daily for five days.
• Platelet function tests and coagulation factor levels were monitored throughout the study period.

Main Results:

• No significant changes in platelet function or coagulation factors were observed in the overall patient group.
• Three patients experienced marked alterations, but these were linked to clinical complications unrelated to cefotetan.
• Patients had normal renal function during the study.

Conclusions:

• Cefotetan does not appear to induce significant hemostatic abnormalities in patients with hepatobiliary disorders and normal renal function.
• The antibiotic demonstrated a favorable safety profile concerning bleeding risks in this high-risk population.
• Further studies may be warranted to confirm these findings in broader patient cohorts.